RiteMED Ciprofloxacin

UTIs, chronic bacterial prostatitis, lower resp tract infections, otitis media, acute sinusitis, skin & skin structure infections, bone & joint infections, complicated intraabdominal infections, infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical & urethral gonorrhea, inhalational anthrax.

UTI Acute uncomplicated: 250 mg every 12 hr for 3 days. Mild/moderate: 250 mg every 12 hr for 7-14 days. Severe: 500 mg every 12 hr for 7-14 days. Chronic bacterial prostatitis Mild/moderate: 500 mg every 12 hr for 28 days. Lower resp tract infection Mild/moderate: 500 mg every 12 hr for 7-14 days. Severe/complicated: 750 mg every 12 hr for 7-14 days. Acute sinusitis Mild/moderate: 500 mg every 12 hr for 10 days. Skin & skin stricture infection Mild/moderate: 500 mg every 12 hr for 7-14 days. Severe/complicated: 750 mg every 12 hr for 7-14 days. Bone & joint infection Mild/moderate: 500 mg every 12 hr for 4-6 days. Severe/complicated: 750 mg every 12 hr for 4-6 days. Intraabdominal infection Complicated: 500 mg every 12 hr for 7-14 days in conjunction w/ metronidazole. Infectious diarrhea Mild/moderate/severe: 500 mg every 12 hr for 5-7 days. Typhoid fever Mild/moderate: 500 mg every 12 hr for 10 days. Urethral & cervical gonococcal infection Uncomplicated: 250 mg as single dose. Inhalational anthrax (post-exposure) Adult 500 mg every 12 hr for 60 days. Childn <18 yr 15 mg/kg/dose every 12 hr for 60 days. Max: Not to exceed 500 mg/dose. Renal impairment CrCl 30-50 mL/min 250-500 mg every 12 hr, 5-29 mL/min 250-500 mg every 18 hr, hemodialysis or peritoneal dialysis 250-500 mg every 24 hr (after dialysis).

May be taken with or without food: Do not take w/ dairy products (eg, milk or yogurt) or Ca-fortified juices alone. Take at least 2 hr prior to or 6 hr after Mg/Al antacids, sucralfate, didanosine chewable/buffered tab or ped powd for oral soln, or other Ca, Fe or Zn-containing products.

Hypersensitivity to ciprofloxacin or quinolone antibiotics.

Discontinue use at 1st appearance of skin rash or any other sign of hypersensitivity; if patient experiences tendon pain, inflammation or rupture; if CNS events including dizziness, confusion, tremors, hallucinations, depression & rarely suicidal thoughts or acts occur; if phototoxicity occurs. Not a drug of 1st choice in presumed or confirmed pneumonia secondary to Strep pneumoniae. Not been shown to be effective in syphilis. Convulsions, increased intracranial pressure & toxic psychosis; pseudomembranous colitis. Patients w/ known or suspected CNS disorders that may predispose to seizure threshold (eg, severe cerebral arteriosclerosis, epilepsy) or in presence of other risk factors that may predispose to seizures or lower seizure threshold (eg, certain drug therapy, renal dysfunction). Avoid alkalinity of urine & ensure hydration in patients during treatment. Avoid excessive sunlight. Periodic assessment of organ system functions including renal, hepatic & hematopoietic function in prolonged therapy. Avoid concomitant use w/ theophylline. Caution in driving an automobile or operating machinery, & in activities which may be requiring mental alertness & coordination. Renal impairment. Pregnancy & lactation. Use in ped patients & adolescents <18 yr except for inhalational anthrax (post-exposure).

Nausea, diarrhea, abdominal pain/discomfort, headache, restlessness & rash.

May lead to elevated serum conc & prolongation of elimination t_½ of theophylline. Interferes w/ metabolism of caffeine leading to reduced clearance & prolongation of its serum t_½. Altered serum levels of phenytoin. Transient elevations in serum creatinine w/ cyclosporine. Enhanced anticoagulant effects of oral anticoagulant warfarin or its derivatives. Interfered renal tubular secretion & increased serum levels w/ probenecid.

Quinolones

J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Rx